A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia

Renato Bassan, Monika Brüggemann, Hoi-Shen Radcliffe, Elizabeth Hartfield, Georg Kreuzbauer, and Sally Wetten

Disclosures: Hoi-Shen Radcliffe and Sally Wetten are employees of Amgen Ltd, and Georg Kreuzbauer is an employee of Amgen (Europe) GmbH; these authors have stock ownership in Amgen. Renato Bassan has received honoraria for advisory boards from Amgen Inc., Incyte, Pfizer and Shire. Monika Brüggemann has received honoraria for advisory boards and Speaker Bureaus from Amgen Inc., Hoffman-La Roche Ltd and Incyte, and has received grant/research support from Amgen Research, Regeneron and Affimed Therapeutics. Elizabeth Hartfield was an employee of Oxford PharmaGenesis Ltd at the time that the study was conducted; Oxford PharmaGenesis Ltd has received funding from Amgen.

Contributions: RB, MB, GK, H-SR and SW designed the study. EH performed the systematic literature review. H-SR performed the meta-analysis. All authors interpreted the results of the systematic literature review and meta-analysis, contributed to the development of the manuscript, and approved the final version of the manuscript.